Penetration of atazanavir in seminal plasma of men infected with human immunodeficiency virus type 1

E van Leeuwen; R Ter Heine; F van der Veen; S Repping; J H Beijnen; J M Prins

doi:10.1128/AAC.00774-06

Penetration of atazanavir in seminal plasma of men infected with human immunodeficiency virus type 1

Antimicrob Agents Chemother. 2007 Jan;51(1):335-7. doi: 10.1128/AAC.00774-06. Epub 2006 Oct 30.

Authors

E van Leeuwen¹, R Ter Heine, F van der Veen, S Repping, J H Beijnen, J M Prins

Affiliation

¹ Academic Medical Centre, Obstetrics and Gynecology, H4-205, Meibergdreef 9, 1100 DD Amsterdam, The Netherlands. e.vanleeuwen@amc.uva.nl

Abstract

In this exploratory study, the human immunodeficiency virus (HIV) protease inhibitor atazanavir was detected in seminal plasma in 15 out of 15 HIV-infected men taking an atazanavir-containing regimen. However, this penetration was limited and variable, and the median seminal/blood plasma ratio was only 0.1.

Publication types

Clinical Trial
Research Support, Non-U.S. Gov't

MeSH terms

Anti-HIV Agents / administration & dosage
Anti-HIV Agents / blood
Anti-HIV Agents / pharmacokinetics
Atazanavir Sulfate
Dose-Response Relationship, Drug
HIV Infections / drug therapy*
HIV Infections / metabolism
HIV-1 / drug effects*
Humans
Male
Oligopeptides / administration & dosage
Oligopeptides / blood
Oligopeptides / pharmacokinetics*
Pyridines / administration & dosage
Pyridines / blood
Pyridines / pharmacokinetics*
RNA, Viral / blood
Semen / metabolism*
Time Factors
Treatment Outcome

Substances

Anti-HIV Agents
Oligopeptides
Pyridines
RNA, Viral
Atazanavir Sulfate